Uterine cervix carcinoma in situ
diseaseOn this page
Also known as carcinoma in situ of cervix aJCC v6carcinoma in situ of cervix uteri aJCC v6carcinoma in situ of the cervix aJCC v6carcinoma in situ of the cervix uteri aJCC v6carcinoma in situ of the uterine cervix aJCC v6carcinoma in situ of uterine cervixcarcinoma in situ of uterine cervix aJCC v6cervical cancer stage 0 aJCC v6cervical carcinoma in situ aJCC v6cervical intraepithelial neoplasia grade 3 aJCC v6cervical Severe dysplasia aJCC v6cervix carcinoma in situ aJCC v6cervix intraepithelial neoplasia grade 3 aJCC v6cervix Severe dysplasia aJCC v6cervix uteri carcinoma in situ aJCC v6cervix uteri intraepithelial neoplasia grade 3 aJCC v6cervix uteri Severe dysplasia aJCC v6CIN 3 aJCC v6CIN grade 3 aJCC v6FIGO stage 0 carcinoma of cervix
Summary
Uterine cervix carcinoma in situ (MONDO:0042487) is a cancer and 9 clinical trials. Top therapeutic interventions include celecoxib. A subtype of uterus carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | uterine cervix carcinoma in situ |
| Mondo ID | MONDO:0042487 |
| MeSH | D018290 |
| DOID | DOID:8991 |
| NCIT | C4000 |
| SNOMED CT | 254889004 |
| UMLS | C0851140 |
| MedGen | 163094 |
| Anatomy (UBERON) | UBERON:0000002 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma in situ of cervix aJCC v6 · carcinoma in situ of cervix uteri aJCC v6 · carcinoma in situ of the cervix aJCC v6 · carcinoma in situ of the cervix uteri aJCC v6 · carcinoma in situ of the uterine cervix aJCC v6 · carcinoma in situ of uterine cervix · carcinoma in situ of uterine cervix aJCC v6 · cervical cancer stage 0 aJCC v6 · cervical carcinoma in situ aJCC v6 · cervical intraepithelial neoplasia grade 3 aJCC v6 · cervical Severe dysplasia aJCC v6 · cervix carcinoma in situ aJCC v6 · cervix intraepithelial neoplasia grade 3 aJCC v6 · cervix Severe dysplasia aJCC v6 · cervix uteri carcinoma in situ aJCC v6 · cervix uteri intraepithelial neoplasia grade 3 aJCC v6 · cervix uteri Severe dysplasia aJCC v6 · CIN 3 aJCC v6 · CIN grade 3 aJCC v6 · FIGO stage 0 carcinoma of cervix (+29 more)
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › uterus carcinoma in situ › uterine cervix carcinoma in situ
Related subtypes (1): endometrium carcinoma in situ
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE2 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00577317 | PHASE3 | TERMINATED | Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer |
| NCT00072540 | PHASE2 | WITHDRAWN | S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix |
| NCT00081263 | PHASE2 | COMPLETED | Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia |
| NCT00003384 | Not specified | COMPLETED | Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer |
| NCT01313104 | Not specified | WITHDRAWN | Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer |
| NCT01550783 | Not specified | COMPLETED | Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening |
| NCT02002468 | Not specified | UNKNOWN | Follow-up of Abnormal and Inadequate Smear-test Results |
| NCT02124252 | Not specified | COMPLETED | Community-Driven Cervical Cancer Prevention in Western Kenya |
| NCT02406352 | Not specified | UNKNOWN | Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CELECOXIB | 4 | 2 |
Related Atlas pages
- Drugs: Celecoxib